PharmaShots Weekly Snapshot (March 02-06, 2020)

1. Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19

Published: Mar 06, 2020 | Tags: Mount Sinai, Signs, Multi-Year, Collaboration, Harbour BioMed, Develop, Novel Biotherapies, Multiple Cancer Indications, COVID-19

2. AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV Bladder Cancer

Published: Mar 06, 2020 | Tags: AstraZeneca, Reports, Results, Imfinzi, Tremelimumab, P-III, DANUBE, Study, Unresectable, Stage IV, Bladder Cancer

3. Allergan’s Durysta (bimatoprost implant) Receives the US FDA’s Approval as the First Intracameral Biodegradable Sustained-Release Implant for Patients with OAG and OHT

Published: Mar 05, 2020 | Tags: Allergan, Durysta, bimatoprost implant, Receives, US, FDA, Approval, First, Intracameral, Biodegradable, Sustained-Release Implant, Patients, OAG, OHT

4. Zydus’ Saroglitazar Receives DCGI’s Approval as the World’s First Therapy for Non-Cirrhotic NASH in India

Published: Mar 05, 2020 | Tags: Zydus, Saroglitazar, Receives, DCGI, Approval, World, First Therapy, Non-Cirrhotic, NASH, India

5. Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets

Published: Mar 05, 2020 | Tags: Novartis, Enters, Four-Year, Collaboration, Orionis Biosciences, Tackle, Intractable, Disease Targets

6. The US FDA Informs About Cybersecurity Vulnerabilities in Medical Devices with Bluetooth Low Energy

Published: Mar 04, 2020 | Tags: US, FDA, Informs, About, Cybersecurity Vulnerabilities, Medical Devices, Bluetooth Low Energy

7. Heat Biologics Signs a Research Collaboration with University of Miami to Develop Vaccine Against COVID-19

Published: Mar 05, 2020 | Tags: Heat Biologics, Signs, Research Collaboration, University of Miami, Develop, Vaccine, Against, COVID-19

8. Zuellig Pharma Acquires Alliance Pharma (Cambodge) to Bolster its Presence in Indochina

Published: Mar 05, 2020 | Tags: Zuellig Pharma, Acquires, Alliance Pharma, Cambodge, Bolster, Presence, Indochina

9. Roche’s Actemra (tocilizumab) Receives Approval to Combat Coronavirus Complications in China

Published: Mar 04, 2020 | Tags: Roche, Actemra, tocilizumab, Receives, Approval, Combat, Coronavirus Complications, China

10. Alopexx Signs an Exclusive License Agreement with Shenogen Pharma to Develop and Commercialize DI-LEU16-IL2 for B-Cell Lymphomas in China/Asia

Published: Mar 04, 2020 | Tags: Alopexx, Signs, Exclusive, License Agreement, Beijing Shenogen Pharma, Develop, Commercialize, DI-LEU16-IL2, B-Cell Lymphomas, China, Asia

11. Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE Study with AGN-151587 (EDIT-101) to Treat LCA10

Published:  Mar 04, 2020 | Tags: Allergan, Editas, Report, First Patient Dosing, P-I/II, BRILLIANCE Study, AGN-151587, EDIT-101, Treat, LCA10

12. Vir and Alnylam Expand their 2017 License Agreement to Target COVID-19

Published: Mar 04, 2020 | Tags: Vir, Alnylam, Expand, 2017, License Agreement, Target, COVID-19

13. Janssen Reports Submission of Ponesimod’s MAA to EMA for the Treatment of Relapsing Multiple Sclerosis

Published: Mar 04, 2020 | Tags: Janssen, Reports, Submission, MAA, EMA, Ponesimod, Treat, Patients, Relapsing Multiple Sclerosis

14. Iktos and SRI Collaborate to Accelerate Discovery and Development of Novel Anti-Viral Therapies

Published: Mar 03, 2020 | Tags: Iktos, SRI, Collaborate, Accelerate, Discovery, Development, Novel, Anti-Viral Therapies

15. Alnylam’s Givlaari (givosiran) Receives EC’s Approval for Acute Hepatic Porphyria in Adults and Adolescents

Published: Mar 03, 2020 | Tags: Alnylam, Givlaari, givosiran, Receives, EC, Approval, Acute Hepatic Porphyria, AHP, Adults, Adolescents

16. Takeda to Initiate the Development of Plasma-Derived Therapy to Treat Corona Virus (COVID-19)

Published: Mar 04, 2020 | Tags: Takeda, Initiate, Development, Plasma-Derived Therapy, Treat, Corona Virus, COVID-19

17. Roche’s Elecsys GALAD scores Receive the US FDA’s Breakthrough Device Designation for Earlier Diagnosis of Hepatocellular Carcinoma

Published: Mar 03, 2020 | Tags: Roche, Elecsys GALAD scores, Receives, US, FDA, Breakthrough Device Designation, Earlier Diagnosis, Hepatocellular Carcinoma

18. BMS Collaborates with Voluntis to Co-Develop Digital Therapies to Treat Cancer Indications

Published: Mar 03, 2020 | Tags:  BMS, Collaborates, Voluntis, Co-Develop, Digital Therapies, Cancer

19. Novartis’ Mayzent Receives Health Canada’s Approval for Secondary Progressive Multiple Sclerosis with Active Disease

Published: Mar 03, 2020 | Tags: Novartis, Mayzent, Receives, Health Canada, Approval, Secondary Progressive Multiple Sclerosis, Active Disease

20. Lucid Diagnostics Collaborates with the University of Pennsylvania to Evaluate EsoCheck in Patients with Eosinophilic Esophagitis

Published: Mar 02, 2020 | Tags: Lucid Diagnostics, Collaborates, University of Pennsylvania, Evaluate, EsoCheck, Patients, Eosinophilic Esophagitis

21.  Genentech’s Esbriet (pirfenidone) Receives FDA’s Breakthrough Therapy Designation for Unclassifiable Interstitial Lung Disease

Published: Mar 03, 2020 | Tags: Genentech, Esbriet, pirfenidone, Receives, FDA, Breakthrough Therapy Designation, Unclassifiable, Interstitial Lung Disease

22.  Insulet to Halt Study of Omnipod Horizon Due to Software Anomaly

Published: Mar 03, 2020 | Tags: Insulet, Discontinue, Study, Omnipod Horizon, Software Anomaly

23. Thermo Fisher Scientific to Acquire QIAGEN for ~$11.5B

Published: Mar 03, 2020 | Tags: Thermo Fisher Scientific, Acquire, QIAGEN, ~$11.5B

24. Sanofi’s Sarclisa (isatuximab-irfc) Receives the US FDA’s Approval for Relapsed Refractory Multiple Myeloma

Published: Mar 02, 2020 | Tags: Sanofi, Sarclisa, isatuximab-irfc, Receives, US, FDA, Approval, Relapsed Refractory Multiple Myeloma

25. uniQure Signs an Exclusive Research and License Agreement with Gen-X to Develop Novel Synthetic Promoters

Published: Mar 02, 2020 | Tags: uniQure, Signs, Exclusive, Research, License Agreement, Gen-X, Develop, Novel Synthetic Promoters

26. Pfizer and Eli Lilly Report the US FDA Acceptance of BLA for Tanezumab to Treat Chronic Pain Due to Moderate-to-Severe Osteoarthritis

Published: Mar 02, 2020 | Tags: Pfizer, Eli Lilly, Report, US, FDA, Acceptance, BLA, Tanezumab, Treat, Chronic Pain, Moderate-to-Severe, Osteoarthritis

27. Gilead to Acquire Forty Seven for $4.9B

Published: Mar 02, 2020 | Tags: Gilead, Acquire, Forty Seven, $4.9B

28. Takeda to Divest a Portfolio of Select OTC and Non-Core Assets to Hypera Pharma in Latin America for $825M

Published: Mar 02, 2020 | Tags: Takeda, Divest, Portfolio, Select OTC, Non-Core Assets, Hypera Pharma, Latin America, $825M

29. Medexus Acquires Aptevo BioTherapeutics for its Hematology Asset IXINITY

Published: Feb 28, 2020 | Tags: Medexus, Acquires, Aptevo BioTherapeutics, Hematology Asset, IXINITY

30. Boehringer Ingelheim’s Nintedanib Receives CHMP’s Positive Opinion to Treat Systemic Sclerosis-Associated Interstitial Lung Disease

Published: Feb 28, 2020 | Tags: Boehringer Ingelheim, Nintedanib, Receives, CHMP, Positive Opinion, Treat, Systemic Sclerosis-Associated Interstitial Lung Disease

31. Merck KGaA’s ERBITUX (cetuximab) Receives NMPA’s Approval as a 1L treatment for Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Published: Mar 02, 2020 Tags: Merck KGaA, ERBITUX, cetuximab, Receives, NMPA, Approval, 1L, Treatment, Recurrent/ Metastatic, Squamous Cell Carcinoma of Head and Neck

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post